glp-1 market forecast Drugs Size to Hit USD 132.79 Bn by 2035 GLP-1 Receptor Agonist Market Size,

Novo Nordisks Canadian patent didnt expire on schedule

Its usually set between 500-2000 mcg daily

Structural changes such as cardiomyopathy, cardiac hypertrophy, interstitial cardiac fibrosis, endothelial dysfunction, and contractile protein failure can result from elevated oxidative stress in cardiac tissue (Emran et al

Incretins have been studied for more than 140 years, but advancements in the 2010s and 2020s highlight two: GIP (glucose-dependent insulinotropic polypeptide), from the upper gut, and GLP-1 (glucagon-like peptide-1), from the lower gut

The risk of NAION may be as much as 7 times higher when GLP-1 medications are used

Baseline considerations it lists include an A1C above 7.5 percent, BMI, kidney function and cardiovascular disease status